Citicoline (Cytidine-5'-diphosphocholine) is a naturally occurring endogenous nucleotide and an essential intermediate in the synthesis of phosphatidylcholine, a major component of neuronal membranes. It functions as a neuroprotective and neurorestorative agent, enhancing cerebral metabolism, increasing levels of neurotransmitters, and stabilizing cell membranes. In the Indian context, it is widely prescribed for acute ischemic stroke, traumatic brain injury, and cognitive disorders.
Adult: 500 mg to 2000 mg per day in 1-2 divided doses. For acute ischemic stroke: 1000 mg IV twice daily for up to 6 weeks, followed by 500-1000 mg orally twice daily. For chronic conditions: 500-1000 mg orally once or twice daily.
Note: Oral: Tablet/Capsule should be swallowed whole with a glass of water, with or without food. Taking with food may reduce rare gastrointestinal discomfort. Do not crush or chew. For IV administration (hospital setting): Dilute in appropriate IV fluid (e.g., 5% Dextrose) and infuse over 30-60 minutes.
Citicoline exerts its effects via a multi-modal mechanism: 1) It provides choline and cytidine, precursors for the synthesis of phosphatidylcholine (a key neuronal membrane phospholipid), promoting membrane repair and integrity. 2) It increases the synthesis of acetylcholine, a critical neurotransmitter for memory and cognition. 3) It reduces the accumulation of free fatty acids (like arachidonic acid) post-ischemia, thereby mitigating oxidative stress and apoptosis. 4) It enhances cerebral metabolism by increasing glucose utilization and ATP production.
Pregnancy: Category B: Animal reproduction studies have shown no risk, but no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus.
Driving: Citicoline is not sedating and typically improves cognitive alertness. However, if dizziness or blurred vision occurs, patients should avoid driving or operating machinery.
| Levodopa/Carbidopa | Citicoline may potentiate the therapeutic effects of Levodopa, possibly allowing for dose reduction. Monitor for dyskinesias. | Moderate |
| Antihypertensives (e.g., Beta-blockers, ACE inhibitors) | Additive hypotensive effect, especially with IV Citicoline. Monitor blood pressure. | Moderate |
| Cholinergic agents (e.g., Donepezil, Rivastigmine) | Theoretical additive cholinergic effects. Synergistic benefit possible, but monitor for excessive cholinergic side effects (nausea, diarrhea, bradycardia). | Moderate |
| Anticoagulants/Antiplatelets (e.g., Warfarin, Clopidogrel) | No known pharmacokinetic interaction. However, as used in stroke, ensure concurrent therapy is managed by a physician. | Minor |
Same composition (Citicoline (500mg)), different brands: